|
COPYRIGHT 2006 PR Newswire Association LLC
REVLIMID(R) in Combination With Dexamethasone Granted Approval by FDA for Treatment of Multiple Myeloma
NEW YORK, June 29 /PRNewswire/ -- The approval of Revlimid demonstrates that dramatic progress is being made in the treatment of multiple myeloma in extending survival and increasing quality of life.
Blood cancers are the second leading cause of death among all cancers, and as...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
